The estimated Net Worth of Richard Bartram is at least 892 千$ dollars as of 3 April 2019. Mr Bartram owns over 8,000 units of Esperion Therapeutics stock worth over 19,300$ and over the last 7 years he sold ESPR stock worth over 343,040$. In addition, he makes 529,750$ as CFO & Corp. Sec. at Esperion Therapeutics.
Mr has made over 2 trades of the Esperion Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,000 units of ESPR stock worth 343,040$ on 3 April 2019.
The largest trade he's ever made was exercising 17,892 units of Esperion Therapeutics stock on 2 January 2018 worth over 66,200$. On average, Mr trades about 3,237 units every 57 days since 2018. As of 3 April 2019 he still owns at least 11,092 units of Esperion Therapeutics stock.
You can see the complete history of Mr Bartram stock trades at the bottom of the page.
Richard B. Bartram is the CFO & Corp. Sec. at Esperion Therapeutics.
As the CFO & Corp. Sec. of Esperion Therapeutics, the total compensation of Mr Bartram at Esperion Therapeutics is 529,750$. There are 2 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of 1,080,850$.
Mr Bartram is 39, he's been the CFO & Corp. Sec. of Esperion Therapeutics since . There are 13 older and 1 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.
Over the last 11 years, insiders at Esperion Therapeutics have traded over 197,978,412$ worth of Esperion Therapeutics stock and bought 6,755,593 units worth 134,445,709$ . The most active insiders traders include Patrick G Enright、Target N Vbb Biotech Ag Bio...、Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of 145,621$. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth 411$.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: